Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, A., McCarthy, N., . . . Carmichael, J. (2013). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Chicago Style (17th ed.) CitationDent, R., et al. Phase I Trial of the Oral PARP Inhibitor Olaparib in Combination with Paclitaxel for First- or Second-line Treatment of Patients with Metastatic Triple-negative Breast Cancer. 2013.
MLA (9th ed.) CitationDent, R., et al. Phase I Trial of the Oral PARP Inhibitor Olaparib in Combination with Paclitaxel for First- or Second-line Treatment of Patients with Metastatic Triple-negative Breast Cancer. 2013.
Warning: These citations may not always be 100% accurate.